Zdrowie i gospodarka · 16/10/2018
FDA Releases Final Guidance on Developing Targeted Therapies for Rare Molecular Subsets of Diseases
The FDA has released a final guidance for industry on developing targeted therapies for diseases caused by rare molecular alterations, incorporating public comments received since the draft guidance was published in December 2017.
Source: Federal Register — Food and Drug AdministrationOpen original release →